Combination treatment to make liver cancer removable
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three treatments—radiation therapy (SBRT), an immunotherapy drug (camrelizumab), and a targeted therapy (apatinib)—to see if they can shrink liver cancer enough to make surgery possible. It is for people whose liver cancer cannot be removed right now.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of liver cancer called hepatocellular carcinoma.
- Your liver cancer is at a stage where surgery to remove it is not currently possible.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
- Your liver function is well preserved (Child-Pugh class A).
- You do not have an active autoimmune disease or a weakened immune system (such as HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and high-precision radiation (SBRT) to shrink large or multiple liver tumors in people with hepatocellular carcinoma, with the goal of making them small enough for surgery. It's for people who cannot currently have their tumors removed but might become eligible after treatment.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study tests a combination of treatments to shrink liver cancer that cannot be removed with surgery at first. The goal is to make the tumor small enough for surgery or to disappear completely, and then either have surgery or continue the treatment.
Hear when a new Unresectable Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.